- Home
- CHGG vs OTLK Comparison
CHGG vs OTLK Comparison
Compare CHGG & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHGG | OTLK |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 101.3M |
| IPO Year | 2013 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CHGG | OTLK |
|---|---|---|
| Price | $0.98 | $0.66 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.42 | ★ $4.50 |
| AVG Volume (30 Days) | 1.3M | ★ 8.1M |
| Earning Date | 02-23-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,733,000.00 | $1,413,535.00 |
| Revenue This Year | N/A | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.60 |
| 52 Week High | $1.90 | $3.39 |
Technical Indicators
Market Signals| Indicator | CHGG | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 23.93 |
| Support Level | $0.92 | $1.78 |
| Resistance Level | $1.01 | $2.03 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 67.44 | 2.93 |
Price Performance
Historical ComparisonAbout CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.